Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 96

Results For "24"

2058 News Found

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
News | November 06, 2024

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.


Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr
News | November 06, 2024

Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024


Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
News | November 06, 2024

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24


Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
News | November 06, 2024

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities


Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr
News | November 05, 2024

Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr

The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024


Imtiyaz Basade appointed Senior VP of NATCO Pharma
People | November 05, 2024

Imtiyaz Basade appointed Senior VP of NATCO Pharma

He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.


Emcure Pharma forms subsidiary to strengthen dermatology portfolio
News | November 04, 2024

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore


Briefs: Sun Pharmaceutical Industries and Biocon Biologics
News | November 04, 2024

Briefs: Sun Pharmaceutical Industries and Biocon Biologics

The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI